Vestmark Advisory Solutions Inc. reduced its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Get Rating) by 28.6% in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 3,433 shares of the biotechnology company’s stock after selling 1,374 shares during the quarter. Vestmark Advisory Solutions Inc.’s holdings in Sarepta Therapeutics were worth $379,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in SRPT. PNC Financial Services Group Inc. boosted its stake in Sarepta Therapeutics by 189.1% during the 1st quarter. PNC Financial Services Group Inc. now owns 5,784 shares of the biotechnology company’s stock valued at $452,000 after purchasing an additional 3,783 shares in the last quarter. Healthcare of Ontario Pension Plan Trust Fund bought a new position in Sarepta Therapeutics during the 1st quarter valued at $185,000. MetLife Investment Management LLC bought a new position in Sarepta Therapeutics during the 1st quarter valued at $421,000. Great West Life Assurance Co. Can boosted its stake in Sarepta Therapeutics by 6.6% during the 1st quarter. Great West Life Assurance Co. Can now owns 4,541 shares of the biotechnology company’s stock valued at $377,000 after purchasing an additional 281 shares in the last quarter. Finally, Dimensional Fund Advisors LP boosted its stake in Sarepta Therapeutics by 12.3% during the 1st quarter. Dimensional Fund Advisors LP now owns 179,294 shares of the biotechnology company’s stock valued at $14,007,000 after purchasing an additional 19,660 shares in the last quarter. 87.31% of the stock is owned by institutional investors.
Analysts Set New Price Targets
SRPT has been the subject of a number of research reports. The Goldman Sachs Group increased their price target on Sarepta Therapeutics from $152.00 to $171.00 and gave the company a “buy” rating in a research note on Thursday, November 3rd. SVB Leerink reissued an “outperform” rating and set a $160.00 price objective on shares of Sarepta Therapeutics in a research note on Friday, January 20th. Needham & Company LLC raised their price objective on Sarepta Therapeutics from $158.00 to $160.00 and gave the stock a “buy” rating in a research note on Tuesday, January 10th. Morgan Stanley raised their price objective on Sarepta Therapeutics from $135.00 to $141.00 and gave the stock an “equal weight” rating in a research note on Thursday, October 13th. Finally, Cantor Fitzgerald raised their price objective on Sarepta Therapeutics from $150.00 to $174.00 in a research note on Tuesday, December 13th. Three investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat.com, Sarepta Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $150.14.
Insider Buying and Selling at Sarepta Therapeutics
Sarepta Therapeutics Stock Up 0.0 %
Sarepta Therapeutics stock opened at $128.37 on Wednesday. The stock has a market cap of $11.27 billion, a P/E ratio of -15.64 and a beta of 1.04. The company has a quick ratio of 3.99, a current ratio of 4.36 and a debt-to-equity ratio of 3.58. Sarepta Therapeutics, Inc. has a twelve month low of $61.28 and a twelve month high of $134.08. The company’s 50-day moving average price is $122.74 and its two-hundred day moving average price is $111.59.
Sarepta Therapeutics (NASDAQ:SRPT – Get Rating) last announced its earnings results on Wednesday, November 2nd. The biotechnology company reported ($2.94) EPS for the quarter, missing the consensus estimate of ($1.21) by ($1.73). The business had revenue of $230.30 million for the quarter, compared to the consensus estimate of $234.55 million. Sarepta Therapeutics had a negative return on equity of 97.37% and a negative net margin of 81.76%. The firm’s revenue for the quarter was up 21.6% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.60) earnings per share. As a group, analysts expect that Sarepta Therapeutics, Inc. will post -8.09 EPS for the current year.
Sarepta Therapeutics Profile
Sarepta Therapeutics, Inc is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.
- Get a free copy of the StockNews.com research report on Sarepta Therapeutics (SRPT)
- Pliant Therapeutics Gaps 34% Higher: More Upside To Come?
- How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?
- Is the Pain Over for Baudax Bio Investors after a 70% Spike?
- Will Rocket Lab’s First U.S. Launch Send Stock Into Stratosphere?
- 3 Retail Stocks Ringing the Register in 2023
Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.